A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial comb...

Descripció completa

Dades bibliogràfiques

Autors principals:	Caroline Lambert, Rahima Jamal, Paméla Thébault, Eftihia Cocolakis, Karl Bélanger, Jeanne Dionne, Jean-François Cailhier, Huy Le, Caroline Letendre, Stéphanie Lepage, Yelena Shechtman, Réjean Lapointe, Wilson H. Miller Jr
Format:	Artigo
Idioma:	Inglês
Publicat:	Taylor & Francis Group 2026-12-01
Col·lecció:	OncoImmunology
Matèries:	Melanoma pembrolizumab NK cells paclitaxel carboplatin PD-1
Accés en línia:	https://www.tandfonline.com/doi/10.1080/2162402X.2026.2631244
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!